作者:Claudiu T Supuran、Fabrizio Briganti、Silvia Tilli、W.Richard Chegwidden、Andrea Scozzafava
DOI:10.1016/s0968-0896(00)00288-1
日期:2001.3
inhibitors of human CA I and CA II (hCA I and hCA II) and bovine CA IV (bCA IV). For the most active compounds, inhibition constants ranged from 10(-8) to 10(-9) M (for isozymes II and IV). Three of the derivatives belonging to this new class of CA inhibitors were also tested as inhibitors of tumor cell growth in vitro. These sulfonamides showed potent inhibition of growth against several leukemia, non-small
新型的锌酶碳酸酐酶的磺酰胺抑制剂(CA,EC 4.2.1.1)是通过在氧化剂(次氯酸钠或次氯酸钠)的存在下,使含氨基,亚氨基或肼基的芳香族或杂环磺酰胺与N,N-二烷基二硫代氨基甲酸酯反应来制备的。碘)。以这种方式合成的N,N-二烷基硫代氨基甲酰基磺酰胺基磺酰胺是人CA I和CA II(hCA I和hCA II)和牛CA IV(bCA IV)的强抑制剂。对于活性最高的化合物,抑制常数范围为10(-8)至10(-9)M(对于同功酶II和IV)。还测试了属于这种新型CA抑制剂的三种衍生物作为体外肿瘤细胞生长的抑制剂。这些磺酰胺类药物对多种白血病,非小细胞肺癌,卵巢癌,黑素瘤,结肠癌,中枢神经系统,肾癌,前列腺和乳腺癌细胞系。具有多个细胞系。观察到GI50值为10-75nM。此处报道的新磺酰胺类药物的抗肿瘤作用机制仍不清楚,但可能涉及抑制在肿瘤细胞膜(CA IX和CA XII)中占主导地位的CA同